Related references
Note: Only part of the references are listed.Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Alexa B. Kimball et al.
LANCET (2023)
Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa A Systematic Review
Samuel Der Sarkissian et al.
JAMA DERMATOLOGY (2022)
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa The SHARPS Randomized Clinical Trial
Falk G. Bechara et al.
JAMA SURGERY (2021)
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study
A. R. J. V. Vossen et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Gerard Bruin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B. Kimball et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?
C. W. Wieland et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process
E. J. Giamarellos-Bourboulis et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)